Creo Medical Group (LON:CREO) Reaches New 52-Week Low – What’s Next?

Shares of Creo Medical Group PLC (LON:CREO – Get Free Report) reached a new 52-week low during trading on Friday. The company traded as low as GBX 9.20 and last traded at GBX 9.26, with a volume of 620,265 shares. The stock had previously closed at GBX 9.85.

Wall Street Analyst Weigh In

Separately, Shore Capital Group reaffirmed a “house stock” rating and set a GBX 40 price objective on shares of Creo Medical Group in a report on Thursday, July 23rd.

Get Our Latest Stock Report on Creo Medical Group

Creo Medical Group Stock Down 6.0%

The stock has a market cap of £41.59 million, a price-to-earnings ratio of -1.85 and a beta of 1.56. The company has a current ratio of 2.79, a quick ratio of 2.19 and a debt-to-equity ratio of 8.09. The firm’s 50 day moving average is GBX 11.04 and its two-hundred day moving average is GBX 12.79.

Creo Medical Group (LON:CREO – Get Free Report) last announced its earnings results on Wednesday, September 30th. The company reported GBX (2) earnings per share (EPS) for the quarter. Creo Medical Group had a negative return on equity of 38.29% and a negative net margin of 268.57%. On average, sell-side analysts predict that Creo Medical Group PLC will post -10.08 EPS for the current year.

Creo Medical Group Company Profile

(Get Free Report)

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy. The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.

Read More

Receive News & Ratings for Creo Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Creo Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.